Ornithine-Transcarbamylase Deficiency – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Ornithine-Transcarbamylase Deficiency – Drugs In Development, 2024 report and make more profitable business decisions.
Ornithine transcarbamylase (OTC) deficiency is a rare X-linked genetic disorder characterized by complete or partial lack of the enzyme OTC. OTC plays an important role in the breakdown and removal of nitrogen in the body (the urea cycle). The lack of the OTC enzyme results in excessive accumulation of nitrogen, in the form of ammonia in the blood (hyperammonemia). Symptoms include vomiting, refusal to eat, progressive lethargy, and coma. Treatment includes nitrogen scavenging agents.
The Ornithine-Transcarbamylase Deficiency drugs in development market research report provide comprehensive information on the therapeutics under development for Ornithine-Transcarbamylase Deficiency, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ornithine-Transcarbamylase Deficiency and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Ornithine-Transcarbamylase Deficiency | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 10 molecules, with 9 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Ornithine-Transcarbamylase Deficiency therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Ornithine-Transcarbamylase Deficiency pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Ornithine-Transcarbamylase Deficiency treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Arcturus Therapeutics Holdings IncBloomsbury Genetic Therapies Ltd
Gene Therapy Research Institution Co Ltd
iECURE
Moderna Inc
NanoCell Therapeutics Inc
Penn Medicine
Poseida Therapeutics Inc
Ultragenyx Pharmaceutical Inc
Unicyte AG
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Ornithine-Transcarbamylase Deficiency reports